U.S. COMPANY FILING
JOHNSON & JOHNSON — Form 10-Q filed 2026-07-23
Filing text preview
J&J's Q2 2026 sales rose 6.6% to $25.31B, net earnings flat at $5.53B. H1 sales up 8.2% to $49.37B, net earnings down 35% to $10.77B due to prior-year talc reserve reversal. Announced $1B acquisition of Firefly Bio and ongoing Orthopaedics separation.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record